CN107073292B - 用于安全和有效的溶栓的方法和组合物 - Google Patents

用于安全和有效的溶栓的方法和组合物 Download PDF

Info

Publication number
CN107073292B
CN107073292B CN201580058489.0A CN201580058489A CN107073292B CN 107073292 B CN107073292 B CN 107073292B CN 201580058489 A CN201580058489 A CN 201580058489A CN 107073292 B CN107073292 B CN 107073292B
Authority
CN
China
Prior art keywords
composition
tpa
subject
bolus
mprouk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580058489.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073292A (zh
Inventor
维克多·古里维希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrombolytic Science LLC
Original Assignee
Thrombolytic Science LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombolytic Science LLC filed Critical Thrombolytic Science LLC
Publication of CN107073292A publication Critical patent/CN107073292A/zh
Application granted granted Critical
Publication of CN107073292B publication Critical patent/CN107073292B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201580058489.0A 2014-11-03 2015-11-03 用于安全和有效的溶栓的方法和组合物 Active CN107073292B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074374P 2014-11-03 2014-11-03
US62/074,374 2014-11-03
PCT/US2015/058878 WO2016073514A2 (en) 2014-11-03 2015-11-03 Methods and compositions for safe and effective thrombolysis

Publications (2)

Publication Number Publication Date
CN107073292A CN107073292A (zh) 2017-08-18
CN107073292B true CN107073292B (zh) 2021-07-02

Family

ID=55910021

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580058489.0A Active CN107073292B (zh) 2014-11-03 2015-11-03 用于安全和有效的溶栓的方法和组合物

Country Status (10)

Country Link
US (2) US11213574B2 (cg-RX-API-DMAC7.html)
EP (2) EP3708226A1 (cg-RX-API-DMAC7.html)
JP (1) JP6826040B2 (cg-RX-API-DMAC7.html)
CN (1) CN107073292B (cg-RX-API-DMAC7.html)
CA (1) CA2966332C (cg-RX-API-DMAC7.html)
DK (1) DK3215221T3 (cg-RX-API-DMAC7.html)
EA (1) EA035358B1 (cg-RX-API-DMAC7.html)
ES (1) ES2788697T3 (cg-RX-API-DMAC7.html)
MX (1) MX383561B (cg-RX-API-DMAC7.html)
WO (1) WO2016073514A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073292B (zh) 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
CN107516010B (zh) * 2017-08-19 2021-02-09 上海矩点医疗科技有限公司 溶栓剂量模型的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015686A (zh) * 2007-02-06 2007-08-15 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
CN101549150A (zh) * 2008-03-31 2009-10-07 刘建宁 尿激酶原及尿激酶原变体在急性心肌梗塞易化经皮冠状动脉介入中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381346A (en) 1979-11-13 1983-04-26 Huasin Syed S Isolation of plasminogen activators useful as therapeutic and diagnostic agents
GB8623823D0 (en) 1986-10-03 1986-11-05 Sandoz Ltd Therapeutic lysis of fibrin blood clots
GB2197195B (en) 1986-10-03 1991-01-23 Sandoz Ltd Improvments in or relating to organic compounds
US5108901A (en) 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
GB8823833D0 (en) 1988-10-11 1988-11-16 Erba Carlo Spa Production of human prourokinase
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク,インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
EP0682700A4 (en) 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US5472692A (en) 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5510330A (en) 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5810767A (en) 1994-05-11 1998-09-22 Localmed, Inc. Method and apparatus for pressurized intraluminal drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5569197A (en) 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
WO1996021224A1 (en) 1994-12-29 1996-07-11 Sony Corporation Disk cartridge
US6759042B2 (en) 1999-06-04 2004-07-06 Thrombotech Ltd Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US6699230B2 (en) 2000-05-10 2004-03-02 Minnesota Medical Physics, Llc Apparatus and method for out-of-hospital thrombolytic therapy
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CN1142278C (zh) 2001-04-04 2004-03-17 刘建宁 一类能被尿激酶或自身激活的尿激酶原变体及其编码基因、制备方法和用途
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US7070958B2 (en) 2003-04-18 2006-07-04 Thrombolytic Science, Inc. Methods of making pro-urokinase mutants
CA2426115A1 (en) 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
JP2006241109A (ja) 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトPセレクチンおよびDSPAα1に対する抗体を含む融合タンパク質
US8071532B2 (en) * 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US20070298024A1 (en) * 2006-06-22 2007-12-27 Thrombolytic Science, Inc. C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CN107073292B (zh) 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015686A (zh) * 2007-02-06 2007-08-15 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
CN101549150A (zh) * 2008-03-31 2009-10-07 刘建宁 尿激酶原及尿激酶原变体在急性心肌梗塞易化经皮冠状动脉介入中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sequential combination thrombolytic therapy for acute myocardial infarction: results of the ProUrokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial;STUART W. ZARICH等;《JACC》;19950831;第26卷(第2期);第375页左栏倒数第1段至右栏第1段,第376页表2 *

Also Published As

Publication number Publication date
EA035358B1 (ru) 2020-06-01
ES2788697T3 (es) 2020-10-22
JP6826040B2 (ja) 2021-02-03
US12590301B2 (en) 2026-03-31
MX383561B (es) 2025-03-14
CN107073292A (zh) 2017-08-18
JP2017533961A (ja) 2017-11-16
DK3215221T3 (da) 2020-05-11
US20220184189A1 (en) 2022-06-16
HK1243666A1 (en) 2018-07-20
CA2966332A1 (en) 2016-05-12
WO2016073514A3 (en) 2016-08-11
CA2966332C (en) 2024-04-16
EP3708226A1 (en) 2020-09-16
WO2016073514A2 (en) 2016-05-12
EA201790969A1 (ru) 2017-11-30
MX2017005793A (es) 2017-10-23
BR112017008749A2 (pt) 2017-12-19
EP3215221A4 (en) 2018-08-08
EP3215221A2 (en) 2017-09-13
US11213574B2 (en) 2022-01-04
EP3215221B1 (en) 2020-02-26
US20180311322A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
Milling Jr et al. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery
Yasaka et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication
Hyers et al. Antithrombotic therapy for venous thromboembolic disease
Aoki Genetic abnormalities of the fibrinolytic system
US12590301B2 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
Beale et al. ONO‐7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
Coker et al. A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers
Puente et al. Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study
US20240122987A1 (en) Prolyl hydroxylase domain inhibitor treatment to improve survivability of hemorrhagic shock
Cha et al. Bat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential
Shin et al. Albumin therapy in acute stroke patients
WO2019008014A1 (en) MIXTURES OF GASES CONTAINING LOW XENON AND ARGON CONCENTRATIONS PROVIDE NEUROPROTECTION WITHOUT INHIBITING THE CATALYTIC ACTIVITY OF THROMBOLYTIC AGENTS
Xu et al. Oral functional protein Z: Mitigation of thrombosis via thrombin inhibition to prevent cardiovascular disease
US20250041302A1 (en) Prolyl hydroxylase domain inhibitor for treating hemorrhagic or burn shock
Kambara et al. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Sansilvestri-Morel et al. S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism
Shah et al. The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue?
HK1243666B (en) Methods and compositions for safe and effective thrombolysis
US11154596B2 (en) Methods for thrombolysis
BR112017008749B1 (pt) Composição para o uso no tratamento de um sujeito com sintomas de um acidente vascular cerebral ou infarto do miocárdio agudo, kits e usos da mesma
Tracy et al. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
JP2001520200A (ja) ウロキナーゼタイプのプラスミノーゲン活性化因子の内在化および分解を促進するための組成物および方法
US20060233786A1 (en) Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
DRAGHICI et al. Unexpected Bleeding Normal Coagulation Tests: Congenital Factor XIII Deficiency
FAST What happens during a stroke

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant